An emergent, high-fatality lung disease in systemic juvenile arthritis
Preprint
Abstract
Objective To investigate characteristics and risk factors of a novel parenchymal lung disease, increasingly detected in systemic juvenile idiopathic arthritis (sJIA). Methods In a multi-center retrospective study, 61 cases were investigated, using physician-reported clinical information and centralized analyses of radiologic, pathologic and genetic data. Results Lung disease (LD) was associated with distinctive features, including acute erythematous clubbing and a high frequency of anaphylactic reactions to the IL-6 inhibitor, tocilizumab. Serum ferritin elevation and/or significant lymphopenia preceded LD detection. The most prevalent chest CT pattern was septal thickening, involving the periphery of multiple lobes +/- ground glass opacities. Predominant pathology (23/36) was pulmonary alveolar proteinosis and/or endogenous lipoid pneumonia (PAP/ELP), with atypical features, including regional involvement and concomitant vascular changes. Apparent severe delayed drug hypersensitivity occurred in some cases. 5-year survival was 42%. Whole-exome sequencing (20/61) did not identify a novel monogenic defect PAP-related or macrophage activation syndrome (MAS)-related mutations as likely primary cause. Trisomy 21 (T21) increased LD risk, as did young sJIA onset. Refractory sJIA was not required for LD development. Exposure to interleukin (IL)-1 and IL-6 inhibitors (46/61) was associated with multiple LD features. By several indicators, severity of sJIA was comparable in drug-exposed subjects and published sJIA cohorts. MAS at sJIA onset was increased in the drug-exposed, but it was not associated with LD features. Conclusions A rare, life-threatening LD in sJIA is defined by a constellation of unusual clinical characteristics. The pathology, a PAP/ELP variant, suggests macrophage dysfunction. Inhibitor exposure may promote LD, independent of sJIA severity, in a small subset of treated patients. Treatment/prevention strategies are needed.Keywords
All Related Versions
- Published version: Annals of the Rheumatic Diseases, 78 (12), 1722.
This publication has 79 references indexed in Scilit:
- The Role of Interleukin-1 and Interleukin-18 in Pro-Inflammatory and Anti-Viral Responses to Rhinovirus in Primary Bronchial Epithelial CellsPLOS ONE, 2013
- Single ABCA3 Mutations Increase Risk for Neonatal Respiratory Distress SyndromePediatrics, 2012
- Interleukin-1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33Journal of Experimental Medicine, 2012
- Inhibiting NF-κB in the developing lung disrupts angiogenesis and alveolarizationAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2012
- Systemic Arthritis in Children: A Review of Clinical Presentation and TreatmentInternational Journal of Inflammation, 2011
- Infections and immunodeficiency in Down syndromeClinical and Experimental Immunology, 2011
- Genetic Disorders of Surfactant DysfunctionPediatric and Developmental Pathology, 2009
- Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA Journal of Experimental Medicine, 2008
- Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRα gene in the X chromosome pseudoautosomal region 1Journal of Experimental Medicine, 2008
- Diffuse Lung Disease in Young ChildrenAmerican Journal of Respiratory and Critical Care Medicine, 2007